LaBrosse Nicole
SEC CIK 1910662 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| HALO | HALOZYME THERAPEUTICS, INC. | SVP, CFO | 38.5K | — | $3.91M | 32 | 2022-02-10 | 2026-02-20 |
Most active insiders at HALO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Torley Helen | Pres AND CEO, Dir | — | $39.85M |
| 2 | Caudill Cortney | SVP, COO | — | $2.23M |
| 3 | Posard Matthew L. | Dir | — | $2.05M |
| 4 | Connaughton Bernadette | Dir | — | $989.9K |
| 5 | Krishnan Mahesh | Dir | — | $547.8K |
| 6 | LaBrosse Nicole | SVP, CFO | — | — |
| 7 | Snyder Mark Howard | SVP, CLO | — | — |
| 8 | Appelhans Dannielle | Dir | — | — |
| 9 | Lang James Paul | Dir | — | — |
| 10 | DUNCAN BARBARA GAYLE | Dir | — | — |
Transactions 32
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-24 | 2026-02-20+ | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | F - Tax | $70.79 | -6,484 | 38.5K | -14% | -$459.0K |
| DM | 2026-02-24 | 2026-02-20+ | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | +12.0K | 38.3K | +46% | $0 |
| DM | 2026-02-17 | 2026-02-16 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | F - Tax | $79.44 | -12.9K | 26.9K | -32% | -$1.02M |
| DM | 2026-02-17 | 2026-02-16 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | +23.8K | 29.8K | +397% | $0 |
| M | 2025-09-23 | 2025-09-22 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | S - Sale | $77.95 | -2,227 | 22.1K | -9% | -$173.6K |
| DM | 2025-09-11 | 2025-09-10 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | S - Sale+OE | $75.71 | -20.0K | 24.3K | -45% | -$1.51M |
| DM | 2025-09-11 | 2025-09-10 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $12.11 | +12.4K | 44.3K | +39% | +$150.2K |
| D | 2025-02-24 | 2025-02-23 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | F - Tax | $57.75 | -3,601 | 31.9K | -10% | -$208.0K |
| D | 2025-02-24 | 2025-02-23 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | +6,688 | 35.5K | +23% | $0 |
| DM | 2025-02-18 | 2025-02-15+ | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | +29.1K | 31.7K | +1,120% | $0 |
| DM | 2025-02-18 | 2025-02-15+ | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | F - Tax | $58.29 | -15.8K | 26.4K | -37% | -$918.2K |
| DM | 2024-07-23 | 2024-07-22 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $22.50 | +5,000 | 19.5K | +35% | +$112.5K |
| DM | 2024-07-23 | 2024-07-22 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | S - Sale+OE | $53.93 | -5,000 | 15.5K | -24% | -$269.6K |
| DM | 2024-06-28 | 2024-06-26+ | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $22.50 | +30.0K | 25.5K | New | +$675.0K |
| DM | 2024-06-28 | 2024-06-26+ | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | S - Sale+OE | $51.93 | -30.0K | 15.5K | -66% | -$1.56M |
| DM | 2024-02-20 | 2024-02-16 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | +10.4K | 18.3K | +132% | $0 |
| DM | 2024-02-20 | 2024-02-16 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | F - Tax | $36.10 | -5,601 | 15.5K | -27% | -$202.2K |
| D | 2024-02-16 | 2024-02-15 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | F - Tax | $35.91 | -686 | 10.7K | -6% | -$24.6K |
| D | 2024-02-16 | 2024-02-15 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | +1,254 | 11.3K | +12% | $0 |
| D | 2024-02-13 | 2024-02-10 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | +2,502 | 11.6K | +28% | $0 |
| D | 2024-02-13 | 2024-02-10 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | F - Tax | $35.49 | -1,477 | 10.1K | -13% | -$52.4K |
| D | 2023-02-21 | 2023-02-16 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | S - Sale+OE | $49.26 | -2,525 | 9,066 | -22% | -$124.4K |
| D | 2023-02-21 | 2023-02-16 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | +5,094 | 11.6K | +78% | $0 |
| D | 2023-02-17 | 2023-02-15 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | +1,254 | 7,118 | +21% | $0 |
| D | 2023-02-17 | 2023-02-15 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | F - Tax | $49.20 | -621 | 6,497 | -9% | -$30.6K |
| DM | 2023-02-14 | 2023-02-10+ | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | +3,892 | 6,545 | +147% | $0 |
| DM | 2023-02-14 | 2023-02-10+ | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | F - Tax | $48.92 | -2,073 | 5,156 | -29% | -$101.4K |
| M | 2022-11-16 | 2022-11-15 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | S - Sale | $53.81 | -5,000 | 4,410 | -53% | -$269.1K |
| D | 2022-02-17 | 2022-02-15 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | F - Tax | $34.43 | -433 | 9,045 | -5% | -$14.9K |
| D | 2022-02-17 | 2022-02-15 | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | +1,255 | 9,478 | +15% | $0 |
| DM | 2022-02-14 | 2022-02-10+ | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | M - OptEx | $0.00 | +5,148 | 8,650 | +147% | $0 |
| DM | 2022-02-14 | 2022-02-10+ | HALO | HALOZYME THERAPEUTICS, INC. | LaBrosse Nicole | SVP, CFO | F - Tax | $34.47 | -1,958 | 8,223 | -19% | -$67.5K |
Purchase Sale Sale after option exercise All abbreviations